Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$90.23

0.06 (0.07%)

13:30
04/21/17
04/21
13:30
04/21/17
13:30

BioMarin announces positive CHMP opinion in Europe for Brineura

BioMarin Pharmaceutical announced that the Committee for Medicinal Products for Human Use, or CHMP, the scientific committee of the European Medicines Agency, has adopted a positive opinion for the company's Marketing Authorization Application for Brineura to treat children with Neuronal Ceroid Lipofuscinosis Type 2 disease, a form of Batten disease, which is also known as tripeptidyl peptidase 1 deficiency. The CHMP's recommendation is now referred to the European Commission, which is expected to render its final decision by the second quarter of 2017. "The EC typically adheres to the recommendation of the CHMP, but is not obligated to do so. If approved by the EC, BioMarin will receive marketing authorization for Brineura in all 28 countries of the European Union, Norway, Iceland and Liechtenstein," the company stated.

  • 27

    Apr

  • 03

    May

  • 04

    May

  • 04

    May

BMRN BioMarin
$90.23

0.06 (0.07%)

03/22/17
PIPR
03/22/17
NO CHANGE
Target $42
PIPR
Overweight
Theravance one program away from joining Incyte, says Piper Jaffray
After hosting meetings with management, Piper Jaffray analyst Joshua Schimmer reiterates Theravance Biopharma (TBPH) as a top mid-cap pick. The analyst has an Overweight rating on the shares with a $42 price target. Schimmer increasingly sees Theravance as one of the most likely mid-caps to make the jump to be the next Incyte (INCY). The company is just one major program away from joining the ranks of Incyte and BioMarin (BMRN), he tells investors in a research note.
03/29/17
UBSW
03/29/17
INITIATION
Target $92
UBSW
Neutral
BioMarin initiated with a Neutral at UBS
UBS analyst Martin Auster initiated BioMarin with a Neutral rating and $92 price target.
03/30/17
03/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sunoco (SUN) initiated with a Sell at Goldman. 2. CyberArk (CYBR) initiated with an Equal Weight at Morgan Stanley. 3. Humana (HUM) reinstated with an Outperform at Oppenheimer. 4. Qualys (QLYS) initiated with an Overweight at Morgan Stanley. 5. Alexion (ALXN), AveXis (AVXS), and Spark Therapeutics (ONCE) were initiated with a Buy at UBS, while Alnylam (ALNY) and BioMarin (BMRN) were initiated with a Neutral, and United Therapeutics (UTHR) was initiated with a Sell. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/17
FBCO
04/18/17
INITIATION
Target $112
FBCO
Outperform
BioMarin assumed with an Outperform at Credit Suisse
Target $112.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.